sustained release


Also found in: Dictionary, Thesaurus, Legal, Financial, Acronyms, Encyclopedia, Wikipedia.

sustained release

The delivery of a drug from a tablet or other reservoir over many hours or days (instead of minutes or hours), to provide a durable therapeutic effect.
See also: release
References in periodicals archive ?
The application of lipids in sustained release formulations is a growing area of interest.
The sustained release form stays in the body longer for extended absorption, higher muscle retention to extend endurance, speed muscle recovery, build muscle strength and enhance peak performance capabilities.
According to the company, DEXTENZA (sustained release dexamethasone) Intracanalicular Depot is placed through the punctum, a natural opening in the eyelid, into the canaliculus and is designed to deliver dexamethasone to the ocular surface for four weeks.
For example, in the case of sustained release opioids designed to treat pain for 12 hours, patients may be subjected to a 12-hour dose in a matter of minutes.
Contract awarded for indapamide, sustained release film coating tablet 1.5 mg
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) revealed on Tuesday the launch of an exclusive agreement for the distribution in Canada of its sustained release intravitreal implant for the treatment of diabetic macular edema, ILUVIEN.
According to the company, its innovative TransCon technology combines the benefits of prodrug and sustained release technologies to develop a pipeline of best-in-class therapeutics that address significant unmet medical needs.
602-2015 dutasteride tamsulosin sustained release coated tablet 0.4 mg / 0.5 mg
Objective: Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration
The company's range of issued patents and patent applications now includes the release formulations and pharmacokinetic profile of Metadoxine, including the special sustained release, combined release and burst release formulations and the associated methods of treatment, and the clinical utilisation of MDX for cognitive disorders including Alcobra's lead indication, ADHD.
Following this second patent in the US covering MDX, the company's portfolio of issued patents and patent applications now covers the release formulations and pharmacokinetic profile of Metadoxine, the special sustained release, combined release and burst release formulations and the associated methods of treatment, as well as the clinical utilisation of MDX.

Full browser ?